Search results for "Quinidine"
showing 4 items of 14 documents
Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.
2009
Literature data are reviewed relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing quinidine sulfate. Quinidine sulfate's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. The available data are not fully conclusive, but do suggest that quinidine sulfate is highly soluble and moderately to highly permeable and would likely be assigned to BCS Class I (or at worst BCS III). In view of the inconclusiveness of the data and, more imp…
ACTION POTENTIAL, MEMBRANE CURRENTS AND FORCE OF CONTRACTION IN MAMMALIAN HEART MUSCLE FIBRES TREATED WITH QUINIDINE
1978
The effects of quinidine on electrical and mechanical activity were investigated in atrial and/or ventricular heart muscle preparations from guinea pigs and cats. Quinidine (1--100 micrometer) exerted negative inotropic effects in papillary muscles from guinea pigs and cats. In guinea-pig left atria, a positive inotropic effect was superimposed on the negative inotropic effect in response to quinidine. Quinidine (100 micrometer) prolonged the duration of the action potential in guinea-pig atria but shortened it in guinea-pig ventricular muscle. In cat papillary muscles, the late repolarization was markedly prolonged by quinidine, but virtually no change of the plateau phase was observed. Th…
Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.
2003
The influence of the secretion process on the absorption of ciprofloxacin, grepafloxacin and sparfloxacin has been evaluated by means of inhibition studies. Two well known P-glycoprotein inhibitors (cyclosporine, verapamil), a mixed inhibitor of P-glycoprotein and the organic cation transporter OCT1 (quinidine) and a well established MRP substrate (p-aminohipuric acid) have been selected in order to distinguish the possible carriers implicated. An in situ rat gut perfusion model and CACO-2 permeability studies are used. Both methods suggest the involvement of several types of efflux transporters for every fluoroquinolone. The relevance of the secretory pathway depends on the intrinsic perme…
Opioid Inhibition of Oxytocin Release, but not Autoinhibition of Dopamine Release May Involve Activation of Potassium (K+) Channels
1991
ABSTRACT Release of oxytocin (Ox) or dopamine (DA) from the isolated neural lobes or neurointermediate lobes, respectively, was evoked by high K + (30 or 45 mM). Naloxone (1-10 μmol/l) which largely enhances the impulse-induced release of Ox had no effect on Ox release evoked by 30 or 45 mM K + . In the presence of 10 mM tetraethylammonium (TEA), Ox release evoked by 30 or 45 mM K + was increased 2-3fold; nevertheless, naloxone caused a further 2-3fold increase. Barium (500 μM) and quinidine (300 μM) antagonized the effect of naloxone observed in the presence of TEA. (-)-Sulpiride (10 μM) enhanced the release of DA evoked by 30 and 45 mM K + by 94 % and 19 %, respectively. TEA enhanced the …